¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inflammatory reticulosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® pelvic inflammatory disease ÇÑ±Û °ñ¹Ý¿°Áúȯ
¼³¸í   
  °ñ¹ÝÁÖÀ§ÀÇ Àå±â¿¡ ¹ß»ýÇϴ ¿°ÁõÀ» ¸»ÇÔ. ÁַΠ¿©¼º¿¡¼­ ¹ß»ýÇϸ砿øÀÎÀº ÀÓ±Õ(gonococcus)°ú ºñÀÓ±Õ¿¡ ÀÇÇÑ °¨¿°(non-gonorrheal infection)¿¡ ÀÇÇÑ´Ù. Áõ»óÀº Ãʱ⿡´Â ÁúºÐºñ¹°, ÇϺ¹ºÎµ¿Åë, ¿©¼ºÀÇ »ý½Ä±âºÎÀ§¿¡ ¹ß»ýÇϴ ¾ÐÅë, ¿ù°æÅë, ¿ù°æ·®ÀÇ Áõ°¡ µîÀÌ´Ù. ÀÏÂï Ä¡·áÇØ¾ß Çϸç, °è¼ÓÀûÀ¸·Î º´ÀÌ Áö¼Ó½Ã ¿©¼ºÀÇ ºÒÀÓÀÇ ¿øÀÎÀÌ µÈ´Ù. ÈÄÁø±¹¿¡¼­´Â °¡Àå ¸¹Àº ¿©¼ººÒÀÓÀÇ ¿øÀÎÀ̱⵵ ÇÔ. Ä¡·á´Â Ç×»ýÁ¦ÀÇ Åõ¿©ÀÌ´Ù.
¿µ¹® inflammatory bowel disease ÇÑ±Û ¿°Áõ¼ºÃ¢ÀÚº´
¼³¸í   
  À§Àå°üÀ» Ä§¹üÇϴ Á¤È®ÇÑ ¿øÀÎÀÌ ¹àÇôÁöÁö ¾ÊÀº ¸¸¼ºÀûÀΠ¿°Áõ¼º ÁúȯÀ» ¸»ÇÑ´Ù. Å©°Ô ¡®±Ë¾ç¼º ´ëÀå¿°¡¯(ulcerative colitis)°ú ¡®Å©·Ðº´¡¯(Crohn's disease)ÀÇ µÎ Á¾·ù·Î ±¸ºÐµÈ´Ù. ¹éÀÎ, À¯ÅÂÀο¡ ¸¹°í ÈæÀÎÀ̳ª µ¿¾çÀο¡´Â µå¹°Áö¸¸ µ¿¾çÀο¡¼­ Á¡Â÷ Áõ°¡Ãß¼¼¿¡ ÀÖ´Ù. È£¹ß¿¬·ÉÀº 15~35¼¼ »çÀÌÀÌ´Ù. Áõ»óÀº ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì, ¼³»ç(Ç÷º¯ ¹× Á¡¾×º¯), µÚ¹«Á÷, º¹Åë, º¹ºÎ¾ÐÅë, Ã¼Áß°¨¼Ò µîÀÌ ÁַΠ³ªÅ¸³ª¸ç ¡®Å©·Ðº´¡¯¿¡¼­´Â ¼³»ç¿Í Ã¼Áß°¨¼Ò, ¿ìÇϺ¹ºÎ Á¾·ù, Ç×¹®ÁÖÀ§ ÀÌ»ó, º¹ºÎ¾ÐÅë µîÀÌ ³ªÅ¸³­´Ù. Áø´ÜÀº º´·Â°ú ¹æ»ç¼±ÇÐÀû °Ë»ç, Á÷Àå°æ ¹× ´ëÀå ³»½Ã°æ°Ë»ç, Á÷Àå ¹× ´ëÀåÀÇ Á¶Á÷°Ë»ç·Î Çϸç Ä¡·á´Â ³»°úÀûÀΠġ·á°¡ ¿øÄ¢À̳ª ³»°úÀû Ä¡·á¿¡ µèÁö ¾Ê°Å³ª ÇÕº´ÁõÀÌ »ý±æ °æ¿ì¿¡´Â ¿Ü°úÀû Ä¡·á¸¦ ½ÃÇàÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì¿¡´Â ¡®´ëÀå¾Ï¡¯À» ¿¹¹æÇϱâ À§Çؼ­ ¿Ü°úÀû Ä¡·á¸¦ Çϱ⵵ ÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯°ú ¡®Å©·Ð º´¡¯¿Ü¿¡ ¿°Áõ¼º Ã¢ÀÚº´¿¡ ¼ÓÇϴ ¡®º£Ã¼Æ® º´¡¯Àº Àç¹ß¼º ±¸°­³» ±Ë¾ç, ÇǺΠº´º¯, ¾È±¸ºÎ ¿°Áõ, ¿ÜÀ½ºÎ ±Ë¾ç, °üÀý¿° Áõ»ó, À§Ã¢ÀÚ°ü Áõ»ó(º¹Åë, ÀåÃâÇ÷), ºÎ°íȯ¿° µîÀÇ Áõ»óÀ» ³ªÅ¸³»´Âµ¥ Áø´Ü°ú Ä¡·á´Â ¡®±Ë¾ç¼º ´ëÀå¿°¡¯, ¡®Å©·Ð º´¡¯°ú ºñ½ÁÇÏ´Ù.
¿µ¹® anti-inflammatory agent ÇÑ±Û Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
¼³¸í   
  ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇϴ ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇϰԠÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ Àִ ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈ­Á¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³È­ÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È­-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • histiocytic medullary reticulosis
    Á¶Á÷±¸¼ÓÁú±×¹°Áõ, Á¶Á÷±¸¼öÁú¸Á»óÁõ
  • leukemic reticulosis
    ¹éÇ÷º´±×¹°Áõ, ¹éÇ÷º´¸Á»óÁõ
  • lipomelanic reticulosis
    Áö¹æ»ö¼Ò±×¹°Áõ, Áö¹æ»ö¼Ò¸Á»óÁõ
  • polymorphic reticulosis
    ´ÙÇü±×¹°Áõ, ´ÙÇü¸Á»óÁõ
  • pagetoid reticulosis
    ÆÄÁ¦Æ®º´¸ð¾ç±×¹°Áõ, ÆÄÁ¦Æ®º´¸ð¾ç¸Á»óÁõ
  • reticulosis
    ±×¹°Áõ, ¸Á»óÁõ
  • inflammatory
    ¿°Áõ-
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ, ¿°Áõ¼ºÀåÁúȯ
  • inflammatory carcinoma
    ¿°ÁõÇü¾ÏÁ¾
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • inflammatory diarrhea
    ¿°Áõ¼³»ç
  • inflammatory fracture
    ¿°Áõ°ñÀý
  • inflammatory gangrene
    ¿°Áõ±«Àú
  • inflammatory lesion
    ¿°Áõº´ÅÍ, ¿°ÁõȯºÎ
  • inflammatory mediator
    ¿°Áõ¸Å°³Ã¼, ¿°Áõ¸Å°³¹°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reticulosis
    ±×¹°Áõ, ¼¼¸ÁÁõ
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • inflammatory breast cancer
    ¿°ÁõÀ¯¹æ¾Ï
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ
  • pelvic inflammatory disease
    °ñ¹Ý³»°¨¿°
  • inflammatory endometrium
    ¿°ÁõÀڱ󻸷, ¿°ÁõÀڱüӸ·
  • inflammatory
    ¿°Áõ-
  • inflammatory mediator
    ¿°Áõ¸Å°³Ã¼
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • epidermotrophic reticulosis
    Ç¥ÇÇÁöÇâ±×¹°Áõ, Ç¥ÇÇÁöÇâ¼¼¸ÁÁõ
  • histiocytic medullary reticulosis
    Á¶Á÷±¸¼ÓÁú±×¹°Áõ, Á¶Á÷±¸¼ÓÁú¼¼¸ÁÁõ
  • leukemic reticulosis
    ¹éÇ÷º´±×¹°Áõ, ¹éÇ÷º´¼¼¸ÁÁõ
  • lipomelanic reticulosis
    Áö¹æ»ö¼Ò±×¹°Áõ, Áö¹æ»ö¼Ò¼¼¸ÁÁõ
  • malignant mast mast reticulosis
    ¾Ç¼ººñ¸¸¼¼Æ÷±×¹°Áõ, ¾Ç¼ººñ¸¸¼¼Æ÷¼¼¸ÁÁõ
  • medullary histiocytic reticulosis
    ¼ÓÁúÁ¶Á÷±¸¼¼¸ÁÁõ
  • pagetoid reticulosis
    ÆÄÁ¬º´¸ð¾ç±×¹°Áõ, ÆÄÁ¬º´¸ð¾ç¼¼¸ÁÁõ
  • polymorphic reticulosis
    ´ÙÇü±×¹°Áõ, ´ÙÇü¼¼¸ÁÁõ
  • reticulosis
    ±×¹°Áõ, ¼¼¸ÁÁõ
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • cervical inflammatory ectropion
    ¿°ÁõÀڱøñ¿Ü¹øÁõ, ¿°Áõ°æ°ü¿Ü¹øÁõ
  • inflammatory carcinoma
    ¿°Áõ¾ÏÁ¾
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • inflammatory diarrhea
    ¿°Áõ¼³»ç
  • inflammatory bowel disease
    ¿°ÁõâÀÚº´, ¿°ÁõÀ庴
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Pagetoid reticulosis
    ÆÄÁ¬º´¾ç ¸Á»óÁõ
  • polymorphic reticulosis
    ´ÙÇü¸Á»óÁõ
  • polymorphic reticulosis
    ´ÙÇü¼º ¸Á»ó±¸Áõ(¼¼¸ÁÁõ)(Òýû¡àõ ØÑßÒ±¸Áõ(¼¼¸ÁÁõ))
  • Inflammatory response
    ¿°Áõ¹ÝÀÀ(æúñøÚãëë)
  • acute inflammatory demyeliniating
    ±Þ¼º¿°Áõ¼ºÅ»¼öÃʼº(¡­æúñøàõ ÷­âÐÃÊàõ)
  • anti-inflammatory
    Ç׿°Áõ¼º(ù÷æúñøàõ)ÀÇ.
  • anti-inflammatory
    Ç׿°(Áõ)¼º
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • epidermotrophic reticulosis
    Ç¥ÇÇ ÁöÇ⼺ ¸Á»óÁõ
  • histiocytic medullary reticulosis
    Á¶Á÷±¸¼º ¼öÁú¸Á»óÁõ.
  • histiocytic medullary reticulosis
    Á¶Á÷±¸ ¼öÁú ¸Á»óÁõ
  • histiocytic medullary reticulosis
    Á¶Á÷±¸¼º ¼öÁú¸Á»óÁõ
  • leukemic reticulosis
    ¹éÇ÷º´¼º ¼¼¸ÁÁõ(?ËÛËÎÌ¡).
  • lipomelanic reticulosis
    Áö¹æ »ö¼Ò¼º ¸Á»óÁõ
  • malignant mast cell reticulosis
    ¾Ç¼º ºñ¸¸¼¼Æ÷ ¸Á»óÁõ
  • medullary reticulosis, histiocytic
    ¼öÁú¼¼¸ÁÁõ(¸Á»óÁõ)(¡­á¬ØÑñø(ØÑßÒñø), Á¶Á÷±¸¼º(ðÚòÄϰà÷)
  • polymorphic reticulosis
    ´ÙÇü¸Á»óÁõ
  • polymorphic reticulosis
    ´ÙÇü¼º ¸Á»ó±¸Áõ(¼¼¸ÁÁõ)(Òýû¡àõ ØÑßÒ±¸Áõ(¼¼¸ÁÁõ))
  • reticulosis
    ¼¼¸ÁÁõ(á¬ØÑñø)
  • reticulosis, histiocytic medullary
    Á¶Á÷±¸¼º¼öÁú¼¼¸ÁÁõ(¼öÁú¸Á»óÁõ)(ðÚòÄϰà÷âËòõá¬ØÑñø(âËòõØÑßÒñø))
  • sinus reticulosis
    µ¿Ä«Å¸¸£, µ¿¼¼¸ÁÁõ(÷ÓᬠØÑñø).
  • sinus reticulosis
    µ¿Ä«Å¸¸£(Ôס­), µ¿¼¼¸ÁÁõ(÷Óá¬ØÑñø)
  • acute inflammatory demyeliniating
    ±Þ¼º¿°Áõ¼ºÅ»¼öÃʼº(¡­æúñøàõ ÷­âÐÃÊàõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reticulosis
    ¼¼¸ÁÁõ
  • anti-inflammatory
    Ç׿°Áõ¾à, Ç׿°Áõ¼ºÀÇ
  • inflammatory
    ¿°Áõ¼º
  • inflammatory tissue
    ¿°ÁõÁ¶Á÷
  • pelvic inflammatory disease
    °ñ¹Ý¿°Áúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HMR histiocytic medullary reticulosis
LFR lymphoid follicular reticulosis
PAIN pyoderma gangrenosum, aphthous stomatitis, inflammatory eye disease, erythema nodosum [disorders ass...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HMR Histiocytic medullary reticulosis
MMR Midline malignant reticulosis
PR Polymorphic reticulosis
AIDP Acute inflammatory demyelinating polyneuropathy
AIF-1 Allograft Inflammatory Factor-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Omega attachment

    omemtulum

    Omenns syndrome : µ¿ÀǾî=histiocytic medullary reticulosis.

    omental

    ´ë¸ÁÀÇ
  • acute inflammatory demyelinating polyradiculoneuropathy
    ±Þ¼º ¿°Áõ¼º ´Ù¹ß½Å°æ¿°
    ¾ÆÁ÷µµ È®½ÇÇÏÁö ¾ÊÁö¸¸ ¸é¿ª¹ÝÀÀÀ» ÅëÇÏ¿© ³ªÅ¸³­´Ù°í ¾Ë·ÁÁ® ÀÖ´Â ½Å°æº´ÁõÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ±Þ¼ÓÈ÷ ÁøÇàÇÏ´Â ¿îµ¿½Å°æº´ÁõÀ¸·Î ÇÏÁö¿¡¼­ ½ÃÀÛÇÏ¿© »óÁö·Î ÁøÇàµÇ¸ç, Á¤µµÀÇ Â÷À̸¦ °¡Áø °¨°¢Àå¾Ö¸¦ µ¿¹ÝÇÑ´Ù.
  • anti-inflammatory
    Ç׿°Áõ¾à, Ç׿°ÁõÀÇ, Ç׿°Áõ¼ºÀÇ
    ¿°Áõ¿¡ ¹Ý´ë·Î ÀÛ¿ëÇϰųª ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â.
  • anti-inflammatory agent
    Ç׿°Áõ ¾à, ¼Ò¿°Á¦, Ç׿°ÁõÁ¦
    ¿°Áõ¿¡ ¹Ý´ë·Î ÀÛ¿ëÇϰųª ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦.
  • chronic inflammatory trismus
    ¸¸¼º ¿°Áõ¼º ¾Æ°ü±ä±Þ
  • fibrous inflammatory hyperplasia
    ¼¶À¯ ¿°Áõ¼º °úÇü¼º
  • heavier inflammatory component
    ´õ ½ÉÇÑ ¿°Áõ ¿äÀÎ
  • inflammatory
    ¿°Áõ¼º
    ¿°Áõ°ú °ü·ÃµÈ.
  • inflammatory by-product
    ¿°Áõ ºÎ»ê¹°
  • inflammatory cell infiltration
    ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±
    ¿°ÁõÀ» ÀÏÀ¸Å°¸é »ýü´Â ¹æ¾îÀûÀ¸·Î Ȱµ¿ÇÏ°í ¿°Áõ ¹°ÁúÀÇ Á¦°Å, ¿°ÁõÀÇ ÁøÀüÀ» ÀúÁöÇϱâ À§ÇØ ÁÖ·Î Ç÷¾×ÁßÀÇ ¹éÇ÷±¸
  • inflammatory change
    ¿°Áõ º¯È­, ¿°Áõ¼º º¯È­
  • inflammatory diarrhea
    ¿°Áõ¼º ¼³»ç
  • inflammatory disorder
    ¿°Áõ¼º Àå¾Ö
  • inflammatory erythema
    ¿°Áõ¼º È«¹Ý
  • inflammatory gingival hyperplasia
    ¿°Áõ¼º Ä¡Àº Áõ½Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
benign inoculation reticulosis <disease> A self-limiting bacterial infection of the regional lymph nodes (lymphadenitis) caused by afipia felis, a gram-negative bacterium recently identified as bartonella henselae.
It usually arises one or more weeks following a feline scratch, with raised inflammatory nodules at the site of the scratch being the primary symptom. It results in tender and enlarged lymph glands above the site of injury.
A chronic benign adenopathy, especially in children and young adults, commonly associated with a recent cat scratch or bite and caused by bacteria including Bartonella henselae and Alipia felis; the lymphadenopathy usually resolves spontaneously within a period of several months, but complications involving central nervous system, liver, spleen, lung, and skin have been seen.
Synonym: benign inoculation lymphoreticulosis, benign inoculation reticulosis, cat-scratch fever, regional granulomatous lymphadenitis.
(05 Mar 2000)
pagetoid reticulosis A benign localised form of lymphoma with solitary or closely grouped cutaneous tumours consisting of predominantly epidermal infiltration of mononuclear cells resembling those found in mycosis fungoides.
Synonym: pagetoid reticulosis.
(05 Mar 2000)
malignant midline reticulosis An obsolete term for polymorphic reticulosis
(05 Mar 2000)
reticulosis 1. An increase in histiocytes, monocytes, or other reticuloendothelial elements.
2. Obsolete term for lymphoma.
Origin: reticulo-+ G. -osis, condition
(05 Mar 2000)
midline malignant reticulosis granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
polymorphic reticulosis A necrotizing lymphoproliferative lesion with a predilection for the upper respiratory tract. Previously called lethal midline granuloma or malignant midline reticulosis. Treatment is irradiation.
(05 Mar 2000)
leukaemic reticulosis Cancer of the blood due to proliferation of cells of the monocyte series.
Origin: Gr. Haima = blood
(13 Nov 1997)
lipomelanic reticulosis Enlargement of lymph nodes, with proliferation of pale-staining interdigitating reticulum cells and macrophages containing fat and melanin; secondary to various forms of dermatitis.
Synonym: dermatopathic lymphadenitis, lipomelanic reticulosis.
(05 Mar 2000)
acute inflammatory polyneuropathy <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin.
The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months.
Synonym: Guillain-Barre syndrome
(12 Jul 2000)
anti-inflammatory Counteracting or suppressing inflammation.
(18 Nov 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
macrophage inflammatory protein <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other.
They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells.
They most likely also play a significant role in respiratory tract defenses.
(20 Sep 2002)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inflammatory
    ¼±µ¿ÀûÀÎ
  • inflammatory
    ¿°ÁõÀ» ÀÏÀ¸Å°´Â;¿°Áõ¼ºÀÇ;°Ý¾Ó½ÃŰ´Â;¼±µ¿ÀûÀÎ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á